



AFRL-RH-FS-TR-2016-0010

**Observational Study of Human Electrical
Muscle Incapacitation and Cardiac Effects**

**John A. Gibbons
Brian B. Lupfer
Alan Ashworth**

**Human Effectiveness Directorate
Bioeffects Division**

Andrew J. Mojica

KBRwyle Inc.

Mark E. Peele

USARMY MEDCOM Brooke Army Medical Center

Derrick E. Varner

Thermo Fisher Scientific

**May 2016
Final Report**

**Distribution A. Distribution authorized for
public release; distribution unlimited.**

**Air Force Research Laboratory
711th Human Performance Wing
Airman Systems Directorate
Bioeffects Division
4141 Petroleum Drive
Fort Sam Houston, Texas 78234-2644**

NOTICE AND SIGNATURE PAGE

Using Government drawings, specifications, or other data included in this document for any purpose other than Government procurement does not in any way obligate the U.S. Government. The fact that the Government formulated or supplied the drawings, specifications, or other data does not license the holder or any other person or corporation; or convey any rights or permission to manufacture, use, or sell any patented invention that may relate to them.

Qualified requestors may obtain copies of this report from the Defense Technical Information Center (DTIC) (<http://www.dtic.mil>).

Observational Study of Human Electrical Muscle Incapacitation and Cardiac Effects (AFRL-RH-FS-TR-2016-0010) has been reviewed and is approved for publication in accordance with assigned distribution statement.

JOHN A. GIBBONS, LT COL, USAF, MC, CFS
Chief, Aeromedical Services
Bioeffects Division

JIMMY L. FLEMING, DR-III, DAF
Director, Human Effects Center of Excellence

GARRETT D. POLHAMUS, DR-IV, DAF
Chief, Bioeffects Division
Airman Systems Directorate
711th Human Performance Wing
Air Force Research Laboratory

This report is published in the interest of scientific and technical information exchange, and its publication does not constitute the Government's approval or disapproval of its ideas or findings.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) 09-05-2016		2. REPORT TYPE Final		3. DATES COVERED (From - To) 01 Jan 2015 - 09 May 2016	
4. TITLE AND SUBTITLE Observational Study of Human Electrical Muscle Incapacitation and Cardiac Effects				5a. CONTRACT NUMBER N/A	
				5b. GRANT NUMBER N/A	
				5c. PROGRAM ELEMENT NUMBER 62202F	
6. AUTHOR(S) John A. Gibbons, Andrew J. Mojica, Mark E. Peele, Brian B. Lupfer, Derrick F. Varner, Alan Ashworth				5d. PROJECT NUMBER 7757	
				5e. TASK NUMBER HD	
				5f. WORK UNIT NUMBER 06-H0C4	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Human Effects Center of Excellence 711th Airman Systems Wing, Human Effectiveness Directorate, Bioeffects Division 4141 Petroleum Road Fort Sam Houston, Texas 78234-2644				8. PERFORMING ORGANIZATION REPORT NUMBER N/A	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) Air Force Materiel Command, Air Force Research Laboratory, 711th Human Performance Wing, Airman Systems Directorate, Bioeffects Division 4141 Petroleum Road Fort Sam Houston, Texas 78234-2644				10. SPONSOR/MONITOR'S ACRONYM(S) 711 HPW/RHDR	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S) AFRL-RH-FS-TR-2016-0010	
12. DISTRIBUTION / AVAILABILITY STATEMENT Distribution A. Approved for public release; distribution unlimited.					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Human Electrical Muscular Incapacitation (HEMI) is used to subdue combative individuals. Changes in cardiac electrical activity have been proposed as the cause of death in a small fraction of these individuals. A study of 212 patient exposures to < 1000 volts found 28 (14%) developed QT prolongation. The current study sought to determine if changes in QTc interval occur after HEMI exposure. Twenty-four participants had EKG readings before a 5-second HEMI exposure and within 30 minutes after exposure. All subject EKGs were read by a data-blinded cardiac electrophysiologist who calculated a QT corrected (QTc) interval. QTc interval was calculated using Bazett, Fridericia, and Framingham methods. QTc prolongation was defined as >430 ms and a threshold of 30 ms for identifying QTc lengthening. Using the Bazett method, five participants experienced QTc prolongation and six had QTc lengthening. One participant developed QTc prolongation exceeding 500 ms, which carries a risk of developing multifocal ventricular tachycardia. These results suggest that HEMI exposure may cause EKG changes with a risk of ventricular tachycardia.					
15. SUBJECT TERMS electromuscular incapacitation; QT interval; Bazett, Fridericia, Framingham methods; ventricular tachycardia					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT SAR	18. NUMBER OF PAGES 45	19a. NAME OF RESPONSIBLE PERSON J. Fleming
a. REPORT Unclassified	b. ABSTRACT Unclassified	c. THIS PAGE Unclassified			19b. TELEPHONE NUMBER (include area code) (210) 539-8552

THIS PAGE INTENTIONALLY LEFT BLANK

TABLE OF CONTENTS

1.0	LIST OF FIGURES	iv
2.0	LIST OF TABLES.....	v
3.0	LIST OF ACRONYMS.....	vi
4.0	EXECUTIVE SUMMARY.....	vii
5.0	ACKNOWLEDGMENTS.....	viii
6.0	INTRODUCTION.....	1
7.0	MATERIALS AND METHODS	5
7.1	Equipment	5
7.2	Subjects	6
7.3	Data Collection Procedures	7
7.4	Data Analysis	8
8.0	RESULTS	9
8.1	Descriptive Statistics	9
8.2	Change in Heart Rate from Pre- to Post-Exposure.....	10
8.3	Change in QTc Interval Using the Bazett Method	11
8.4	Change in QTc Interval Using the Fridericia Method	13
8.5	Change in QTc Interval Using the Framingham Method	15
8.6	Change in QTc Interval Using a Novel Linear Regression Method.....	17
8.7	Summary QT Interval Change.....	20
8.8	QT Lengthening Versus QT Shortening Analysis.....	21
9.0	DISCUSSION	26
10.0	CONCLUSION.....	29
	REFERENCES	30
	APPENDIX A – Medical Screening Form.....	32
	APPENDIX B – Selvester QRS Screening Criteria	34
	APPENDIX C – Cardiac Medical Conditions Disqualifying for Military Service	35
	APPENDIX D - Rubal Method for Correcting QT Interval Based on RR Interval	36

1.0 LIST OF FIGURES

- Figure 1. Illustration of a single beat on an electrocardiogram
- Figure 2. TASER X-26 output waveform
- Figure 3. Individual subjects' heart rate change
- Figure 4. Individual subjects' QTc change using Bazett method
- Figure 5. Individual subjects' QTc change using Fridericia method
- Figure 6. Individual subjects' QTc change using Framingham method
- Figure 7. QT interval unadjusted for RR interval
- Figure 8. QT interval after linear regression adjustment for RR interval
- Figure 9. Individual subjects' QTc change using Rubal method
- Figure 10. Cardiac action potential
- Figure 11. QT/RR and Rubal Method

2.0 LIST OF TABLES

Table 1.	Descriptive statistics for mean heart rate and QTc interval
Table 2.	Change in heart rate
Table 3.	Change in QTc interval using Bazett method
Table 4.	Change in QTc interval using Fridericia method
Table 5.	Change in QTc interval using Framingham method
Table 6.	Change in QTc interval using Rubal method
Table 7.	Comparison of mean QT interval change calculation methods (n = 24)
Table 8.	Magnitude of QTc exceeding thresholds (n = 24)
Table 9.	QTc shortening versus QTc lengthening (n = 24)
Table 10.	QTc lengthening exceeding thresholds (n = 24)
Table 11.	Comparison of mean QT interval change calculation methods (n = 23)
Table 12.	Magnitude of QTc exceeding thresholds (n = 23)
Table 13.	QTc shortening versus QTc lengthening (n = 23)
Table 14.	QTc lengthening exceeding thresholds (n = 23)
Table 15.	Raw scores for RR Interval (sec), QT Interval (ms), QT/RR, Predicted QT/RR, and QTc (Rubal)
Table 16.	Correlations (R^2) between QTc and RR interval

3.0 LIST OF ACRONYMS

HEMI	Human Electrical Muscle Incapacitation
EKG	Electrocardiogram
TdP	Torsades de Pointes
TASER	Thomas A. Swift Electric Rifle
HR	Heart Rate
FDA	Food and Drug Administration
mA	milliamperes
JBSA	Joint Base San Antonio
HPW	Human Performance Wing
RHD	Bioeffects Division
AFI	Air Force Instruction

4.0 EXECUTIVE SUMMARY

Human electrical muscular incapacitation (HEMI) is widely used to subdue combative individuals. This study examined a possible effect of HEMI on electrical activity of the heart. Twenty-four active duty Security Forces personnel participating in TASER Instructor training volunteered to be subjects. All volunteers were screened for medical exclusions and provided written informed consent. A baseline electrocardiogram (EKG) was obtained before each HEMI exposure. The volunteers then experienced a five second HEMI exposure from an X-26 device. Within 30 minutes of the baseline EKG, a second EKG was obtained. A cardiac electrophysiologist read all of the EKGs without knowing the volunteer identification and before/after status of the EKG data.

The 48 EKGs were analyzed for RR interval, a measure of beat-to-beat heart rate, and QT interval, a measure of the time from initial contraction to relaxation of the heart ventricles. The QT interval was corrected for heart rate (QTc) by four different techniques. Two methods employed a logarithmic adjustment, including the Bazett and Fridericia methods. Two methods employed a linear regression adjustment, which were the Framingham and a novel method, referred to as Rubal for the individual who suggested this data analysis approach.

Overall findings showed a small lengthening in the QTc interval using the Rubal method. No significant change was found in mean heart rate or QTc interval using the Bazett, Fridericia, and Framingham methods. Visual inspection of the data suggested that there were two distinct groups, those whose QTc interval lengthened and those whose QTc interval shortened, with very few having no change. Highly significant changes were seen in these two groups using all four methods for QTc calculation. QTc lengthening reached the borderline threshold of a 30 ms increase for all but the Fridericia method, which showed a 28 ms increase. QTc interval lengthening exceeded 40 ms for about 25% of subjects using all four methods for QTc calculation and exceeded 60 ms for over 10% of subjects. One subject exceeded 500 ms, a threshold state with significant risk for developing ventricular fibrillation.

The results of this study show that significant lengthening of the QT interval can occur after a single 5-second HEMI exposure. Further research is needed to determine if QT interval lengthening is greater with multiple 5-second HEMI exposures, or if HEMI exposure and medications that are known to cause QTc prolongation have an interactive effect on this observed HEMI increase in QTc interval.

5.0 ACKNOWLEDGMENTS

The author wishes to thank the following people for their support of this project.

USAF Security Forces Center: Col (ret) John Probst, Col (ret) Patrick Kelly, MSgt Michael Ellis, TSgt Glenndon Blue, SSgt Joel Mansapit, SSgt Johnathan Dickerson, Mr. Salvador Hernandez, Mr. Albert Respress, and Mr. Rodney Apgar.

USARMY MEDCOM Brooke Army Medical Center: Dr. Bernard Rubal.

Bioeffects Division, 711th Human Performance Wing, Detachment 5, Air Force Research Laboratory: MSgt Samantha Kunzelman, Dr. James Jauchem, Dr. Michael Jirjis, and Mr. W. Brent Voorhees.

The views expressed are those of the authors and do not necessarily reflect those of the U.S. Government, U.S. Department of Defense, the U.S. Air Force, or the U.S. Army.

6.0 INTRODUCTION

Human Electrical Muscular Incapacitation (HEMI) is widely used by law enforcement officials to subdue combative individuals. A small fraction of these individuals subsequently die while in confinement. Critics of HEMI use claim these deaths are a direct effect of HEMI exposure. Changes in the electrical activity of the heart are frequently proposed as the cause. The electrocardiogram (ECG in Europe, EKG in the US) is a routine medical evaluation of cardiac electrical conductivity. Only a small number of human studies have examined EKG changes associated with HEMI exposure. Limitations in each of these studies leave some questions to be answered.

The objective of this study is to evaluate EKGs for electrical conductivity change after a controlled HEMI exposure, specifically investigating change in the QT interval.

Electrical shock has been reported to cause lengthening of the QT interval of an EKG. An Australian study of 212 low voltage (< 1000 volts) exposures found 28 (14%) patients developed QT prolongation, though only three patients had this change longer than six hours.¹ The 14% incidence reported can be used as the upper limit for the effect size of electrical shock reported to cause QT prolongation. The following figure illustrates a full normal cardiac electrical cycle and labels the different segments. The QT interval represents the time from initial contraction to relaxation of the heart ventricles.




Figure 1. Illustration electrical activity of a single heart beat on an electrocardiogram

Prolonged QT interval can lead to development of ventricular tachycardia, in particular polymorphic ventricular tachycardia, also known as torsades de pointes (TdP). TdP may spontaneously revert to normal sinus rhythm or degrade to ventricular fibrillation with subsequent cardiac arrest. There is limited information in the published literature on the electrophysiological cardiac effects of HEMI exposure(s), particularly investigating ventricular electrical activity involving the QT interval.

An observational study of 105 volunteers undergoing HEMI exposure of 3.0 seconds mean interval (range 0.9 – 5 sec) reported volunteers developing both QT shortening and QT lengthening.² Two published EKG strips document QT prolongation for a 2% incidence. This result can be used as a lower limit for the effect size of HEMI shown to cause QT prolongation. Limitations of this study were the use of only four limb leads, use of a single rhythm Lead II monitoring strip, and use of poor quality rhythm strips. QT interval should be assessed in multiple leads for accurate determination. This study likely underestimated the actual occurrence of QT prolongation.

In contrast, another study performed a series of 12-lead EKGs on 32 volunteers including before, immediately after, 16 hours after, and 24 hours after HEMI exposure. Thirty of the 32 baseline EKGs were reported as normal. The two volunteers with abnormal EKGs were noted to have the same findings at the three time points after HEMI exposure. No within subject comparison of before and after changes was performed, including QT interval. This second HEMI study was funded through a grant from TASER, International, and four of the listed authors were consultants for this firm.³ Though it is reassuring that no volunteer was found to develop absolute QT prolongation after HEMI exposure, it is possible that QT lengthening occurred but was not detected due to the absence of before and after comparisons. Also the sample size may have been too small to detect as small as a 2% incidence.

A third study of HEMI exposures obtained baseline 12-lead EKGs for 101 participants, either the day before or morning of exposure, and post-exposure EKGs, after at least 20 but not more than 22 hours. There were no significant mean changes in QT or heart rate-corrected QT (QTc) interval. Post-exposure QTc ranged from 380 to 442 ms. The major limitation of this study is that post-exposure EKGs were obtained 20-22 hours after exposure.⁴

Clinically, the QT interval is corrected for heart rate (HR). Different methods are available to calculate QTc and different thresholds based on gender and age are used to define QT prolongation. Two nonlinear methods, Bazett and Fridericia, and two linear functions, Framingham and Hodges, are commonly used to adjust QT interval based upon heart rate. The Bazett and Fridericia methods were first proposed in 1920. These four methods are shown below.⁵

Bazett $QTc = QT (HR/60)^{1/2}$

Fridericia $QTc = QT (HR/60)^{1/3}$

Framingham $QTc = QT + 154(1 - 60/HR)$

Hodges $QTc = QT + 1.75 (HR - 60)$

Congenital QT prolongation occurs in the U.S. population with prevalence estimates from 1/20,000 to 1/2,500.⁶ QTc prolongation can occur with medications as well. Several anti-arrhythmic drugs are recognized frequently to promote QT prolongation with subsequent development of TdP. This form of ventricular tachycardia can rapidly degenerate into

ventricular fibrillation, with subsequent cardiac arrest. Conversely, torsades de pointes can spontaneously revert to normal sinus rhythm. Classes of medications reported to cause TdP include anti-arrhythmic medications, antipsychotic drugs, antidepressants (primarily tri-cyclic antidepressants), some antihistamines, antimicrobials (including erythromycin, clarithromycin, and ketoconazole), anti-malarial drugs (quinine and chloroquine), methadone, and cocaine.^{7,8,9}

The Bazett method has been used to stratify the risk of developing TdP based upon QTc interval. The risk of cardiac events due to QTc lengthening is estimated as 1.052^x , where x is the increase QTc over 400 ms in multiples of 10 ms.¹⁰ For example, someone with a QTc of 440 ms has a 22% greater risk TdP development than someone with a QTc of 400 ms. A PubMed search was done using the term “risks of QT prolongation.” This search yielded 478 citations, but only a single published provided risk estimation involving QT prolongation. Data from congenital Long QT Syndrome studies indicates that QTc greater than 500 ms carries a 2-3 times higher risk for developing TdP.¹¹ The Food and Drug Administration (FDA) requires pharmaceutical firms to provide QTc results using both the Bazett and Fridericia methods and provide both absolute QTc interval and change from baseline reported during new drug testing. Absolute QTc prolongation threshold values are > 450 ms, > 480 ms, and > 500 ms. QTc interval change from baseline value thresholds are 30 and 60 ms.¹²

QTc variability between EKGs was assessed in one study of 352 healthy subjects. Continuous Holter monitoring was used to record EKGs with subjects at rest during two separate sessions of 10 minutes in a supine position, during 10 minutes of unsupported sitting, and during 15 minutes of unsupported standing. The 95% confidence interval for supine QT variability was within ± 16 ms.¹³ This result is less than the FDA 30 ms threshold and the common clinical 40 ms threshold for QTc prolongation. Thus QTc variability between EKG tracings up to 45 minutes apart did not reach the threshold defined for QTc prolongation. Though not under investigation in the present study, lengthening of QT interval has been shown to be greater during sleep than wake state by 19 ± 7 ms.¹⁴

Data from Holter monitor recordings and 12-lead EKG cannot be compared. A study comparing Holter monitor uncorrected QT interval measurements with simultaneous 12-lead EKG found that lead V1 Holter monitor measurements ranged from 100 ms shorter to 55 ms longer, with a mean of 24 ms shorter, than EKG measurements. Lead V5 results showed that Holter monitor measurements ranged from 42 ms shorter to 62 ms longer, with a mean of 13 ms longer, than EKG measurements.¹⁵ This study did not capture data involving variability of QT interval over time.

Accurate interpretation of QT intervals has been shown to be dependent upon clinical expertise. A study showed two EKGs with congenital QT prolongation and two EKGs from healthy women to four groups of physicians: QT experts, arrhythmia experts, cardiologists, and non-cardiologists. QT intervals were correctly classified by 96% of QT experts, 62% of arrhythmia experts, and less than 25% of cardiologists or non-cardiologists.¹⁶ The limited availability of QT and arrhythmia experts has restricted QT interpretation of EKGs to the data analysis phase of HEMI studies.

In summary, there is scant information in the published literature on the cardiac electrophysiological effects of HEMI, particularly QT interval. The collection of before and after EKGs from volunteers undergoing controlled HEMI exposure permitted an assessment of the risk for QTc changes, a likely immediate event preceding serious injury and death associated with HEMI.

7.1 MATERIALS AND METHODS

7.2 Equipment

A. HEMI device - TASER X-26.

This device was used for all HEMI exposures. It is manufactured by TASER, International. It produces a timed burst of electrical pulses. It was operated in Probe Mode. Specific characteristics per the manufacturer are as follows.¹⁷

Pulse rate	16.5 to 20 pulses per second
Pulse duration	105 to 155 μ sec
Peak load voltage	1,400 to 2,520 volts
Average current	1.5 to 2.4 mA
Energy delivered per pulse	0.095 to 0.125 joules
Power delivered into load	1.8 to 2.3 watts (= joules per second)




Figure 2. TASER X-26 Output Waveform

B. Electrocardiogram (EKG) machine – Burdick Atria 6100

This is an FDA approved medical office device. It was used in accordance with the approved indication to obtain and record 12-lead EKGs from participants. Date and time stamps were inserted on each EKG record. Participant number, rather than name or other identifying information, was entered as the patient name. Ten adhesive electrode pads were applied to the standard four limb and six precordial positions. EKG wires were attached between these electrode pads and the Burdick EKG machine to obtain a baseline 12-lead EKG for each participant. After obtaining a baseline EKG, the EKG wires were removed

but the EKG electrode pads left in place. The same EKG electrode pads were used to obtain a post-exposure 12-lead EKG for each participant. This greatly reduced the time required to obtain a post-exposure EKG.

7.3 Subjects

A. The Active Shooter Incident Response Instructor training courses held at the USAF Security Forces Center, JBSA-Lackland TX, offer 5-second duration HEMI exposures to course participants. All participants are male or female USAF active duty, USAF Reserve, or Air National Guard personnel. All participants are on military orders to attend this course. Over 200 individuals are trained each year. Trainees in each class singly choose to or not to experience HEMI exposure. Every exposed volunteer signed an informed consent form before undergoing a training HEMI exposure.

B. This study enrolled volunteers only from attendees of Active Shooter Incident Response Instructor training courses who had already volunteered for HEMI exposure as part of their training. Twenty-two male and two female participants were recruited. Recruiting was performed through briefings to attendees at the start of the course. Participants received a 711 HPW/RHD Challenge Coin. The coins cost \$12 each to purchase but have no monetary value.

C. Inclusion criteria

1. Male and female personnel 18-55 years of age
2. Participants in the Active Shooter Incident Response Instructor training courses, who had already given written consent for HEMI exposure as part of their training.
3. All participants must be fit for continued world-wide military service as defined in Chapter 5 of AFI 48-123 *Medical Examinations and Standards*.¹⁸

D. Exclusion criteria

1. Personnel with a medical waiver for continued military service.
2. A medical history or recent medication use that may confound the study results. See Appendix A, the Medical Screening Form, for the specific medical screening criteria used.
3. There exists the possibility of abnormal EKG findings that can be disqualifying for continued military service. Most of these conditions are symptomatic, meaning that an individual will know that this condition exists. Some conditions are disqualifying only if they interfere with the satisfactory performance of duty or place the individual at risk for sudden cardiac death. The other symptomatic conditions are indicative of underlying cardiac disease that requires medical management. In both situations, the affected individual is experiencing symptoms and should be under medical care for the relevant condition. The major unexpected risk to a military career is diagnosis of a prior silent heart attack, indicated by the presence of diagnostic Q waves on an EKG, and second degree Type II or third degree heart block, also known as high degree heart block.

The Selvester QRS screening criteria, Appendix B, were used to identify Q-wave infarction. History of a silent heart attack and high degree heart block carry a risk of sudden cardiac death. Identifying individuals with such medical conditions actually provides a long-term benefit greater than the risk of disqualification for continued military service.

Appendix C lists heart conditions that are disqualifying for continued USAF military service. Comments on what the medical terms mean and the associated risks are included.

7.4 Data Collection Procedures

7.3.1 Baseline Pre-exposure EKGs

EKGs before HEMI exposure were obtained from all 24 volunteers. The pre-exposure 12-lead EKGs were obtained in the standard clinical manner with each participant at rest in the supine position. A unique three digit for each subject was the only identifying data entered into the EKG machine or printed on the EKG tracings. A portable examination table was used for the subjects to rest upon. Muscle artifacts were minimized by having each subject place both hands beneath the buttocks when recording data. After the baseline EKGs were recorded, the subjects then queued for HEMI exposure. The EKG electrode pads were left in place and used again for the post-exposure EKGs. All pre-exposure 12-lead EKGs were reviewed by Lt Col Gibbons, Maj Lupfer, or Maj Varner to ensure the absence of any disqualifying medical condition and data acquisition adequacy for interpretation before each participant was disconnected from the EKG machine. A privacy curtain and female chaperone were used when pre-exposure EKGs were obtained from the two female subjects.

7.3.2 HEMI Exposures

All subjects were recruited from students in the Active Shooter Incident Response Instructor training course offered by the Air Force Security Forces Center at JBSA-Lackland, TX. Each student received TASER, International, approved academic training on the bioeffects of HEMI. Students who underwent a HEMI exposure signed an informed consent document as part of the training course. A trained TASER, International, certified Master Instructor verified proper function of the X-26 device and operated the device for all subject exposures. Each subject was supported on either side by another student during the HEMI exposure to prevent an injurious fall. All exposures were done with the subject standing upon a padded sports mat. The X-26 electrodes were attached using alligator clips over the back of the left shoulder and over the back of the right iliac crest. The Master Instructor asked each subject if they were ready prior to starting a countdown to the HEMI exposure. A single 5-second HEMI exposure was delivered to each subject. The alligator clips were removed after the completion of each HEMI exposure.

7.3.3 Post-exposure EKGs

Post-exposure EKGs were obtained after the 5-second HEMI exposure and within 30 minutes of the pre-exposure EKG. The time between the pre- and post-exposure EKGs ranged from 7 minutes 34 seconds to 28 minutes 26 seconds, with a mean interval 15 minutes 34 seconds. Because the EKGs were collected on a non-interference basis with the course activities, it was not possible to control when any given subject was available for obtaining the post-exposure EKG. All post-exposure 12-lead EKGs were reviewed by Lt Col Gibbons, Maj Lupfer, or Maj Varner to ensure data adequacy for interpretation before each participant was disconnected from the EKG machine. After the post-exposure EKG recording was printed, the electrode pads were removed each subject. A privacy curtain and female chaperone were used when post-exposure EKGs were obtained from the two female subjects.

7.4 Data Analysis

All EKGs were read by a cardiac electrophysiologist who was blind to the identity of the subjects. RR interval and QT interval were measured for each of the 48 EKGs. QTc interval calculations were done using the Bazett, Fridericia, Framingham, and a novel linear method (Rubal) to adjust QT interval for heart rate variation.

Test data were analyzed using the open source statistics package R.

8.1 RESULTS

8.2 Descriptive Statistics

Heart rate and QT interval were measured before and after HEMI exposure. Four calculations were used to correct QT interval for heart rate: the Bazett, Fridericia, Framingham, and Rubal methods. Descriptive statistics for the heart rate and corrected QT interval are provided in Table 1.

Table 1

Descriptive statistics for mean heart rate and QTc interval

QTc	<i>M</i>	<i>Mdn</i>	<i>SD</i>	<i>Min</i>	<i>Max</i>
Heart Rate					
Pre	68	69	10.75	46	86
Post	68	68	13.03	43	93
Bazett					
Pre	391	390	30.67	342	452
Post	402	399	45.67	317	539
Fridericia					
Pre	382	381	25.06	332	435
Post	394	392	35.73	327	513
Framingham					
Pre	384	384	25.62	338	435
Post	393	390	37.28	314	505
Rubal					
Pre	414	414	30.69	348	465
Post	432	426	37.38	380	564

Note. M = Mean; Mdn = Median; SD = Standard Deviation.

8.3 Change in Heart Rate from Pre- to Post-Exposure

Table 2

Change in Heart Rate (beats per minute)

Subject ID	Pre	Post	Change
A	59	68	9
B	86	78	-8
C	63	76	13
D	68	62	-6
E	85	74	-11
F	68	59	-9
G	68	52	-16
H	71	76	4
I	83	77	-6
J	77	66	-11
K	82	93	11
L	79	91	12
M	70	62	-8
N	46	56	10
O	56	62	6
P	60	73	14
Q	54	43	-11
R	70	68	-1
S	74	69	-5
T	63	50	-12
U	75	80	5
V	55	51	-4
W	55	63	8
X	71	89	17
Mean	68	68	0




Figure 3. Individual subjects' heart rate change (units = beats per minute). Green dotted line represents decrease heart rate subjects (Pre > Post). Red solid line represents increase heart rate subjects (Pre < Post).

8.4 Change in QTc Interval Using the Bazett Method

The Bazett method is the most common method used in clinical studies for calculating the risk of cardiac events based on QTc interval. This method has been found to consistently over estimate QT intervals for heart rates above 60 beats per minute. It is one of two QTc calculation methods that the FDA requires when a pharmaceutical company submits data about drug effects on QT interval. It is included to provide comparison of these results with other studies.

Table 3

Change in QTc Interval using Bazett Method (ms)

Subject ID	Pre	Post	Change
A	390	383	-7
B	423	442	19
C	428	455	27
D	412	406	-6
E	407	399	-8
F	361	376	15
G	391	353	-38
H	403	412	9
I	438	415	-23
J	418	388	-30
K	416	423	7
L	367	423	56
M	390	381	-9
N	361	387	26
O	342	366	24
P	375	398	23
Q	371	335	-36
R	388	442	54
S	392	367	-25
T	344	317	-27
U	452	539	87
V	404	385	-19
W	361	408	47
X	342	458	116
Mean	391	402	12




Figure 4. Individual subjects' QTc interval change using Bazett method (units = milliseconds). Green dotted line represents decrease heart rate subjects (Pre > Post). Red solid line represents increase heart rate subjects (Pre < Post).

8.5 Change in QTc Interval Using the Fridericia Method

The Fridericia method is the second of two methods for calculating QTc required by the FDA when a pharmaceutical company submits data about drug effects on QT interval. This method is more accurate for estimating QT interval for heart rates above 60 beats per minute. It is included for comparison consistency with the FDA data requirements.

Table 4

Change in QTc interval using Fridericia Method (ms)

Subject ID	Pre	Post	Change
A	391	375	-16
B	398	422	24
C	424	437	13
D	403	404	1
E	384	385	1
F	354	377	23
G	383	361	-22
H	391	396	5
I	395	398	3
J	401	382	-19
K	395	393	-2
L	350	394	44
M	379	378	-1
N	378	391	13
O	346	364	18
P	376	384	8
Q	377	366	-11
R	378	432	54
S	378	359	-19
T	342	327	-15
U	435	513	78
V	409	395	-14
W	366	405	39
X	332	428	96
Mean	382	394	13




Figure 5. Individual subjects' change in QTc interval using Fridericia method (units = ms). Green dotted line represents decrease heart rate subjects (Pre > Post). Red solid line represents increase heart rate subjects (Pre < Post).

8.6 Change in QTc Interval Using the Framingham Method

The Framingham method for calculating QTc is a linear function of the RR interval. One published investigation comparing four different methods for calculating QTc interval found the Framingham method more accurate than the Bazett, Fridericia, and Hodges methods for heart rates over 60 beats per minute.⁵ These data are included for providing best estimates and overall greater data analysis precision.

Table 5

Change in QT interval using Framingham Method (ms)

Subject ID	Pre	Post	Change
A	391	378	-13
B	400	423	23
C	424	436	12
D	405	404	-1
E	388	389	1
F	357	376	19
G	385	355	-30
H	394	398	4
I	415	401	-14
J	403	383	-20
K	398	394	-4
L	356	396	40
M	383	379	-4
N	365	389	24
O	343	365	22
P	376	388	12
Q	373	335	-38
R	382	432	50
S	382	362	-20
T	343	314	-29
U	435	505	70
V	407	390	-17
W	363	406	43
X	338	426	88
Mean	384	393	9




Figure 6. Individual subjects' QTc interval change using Framingham method (units = ms). Green dotted line represents decrease heart rate subjects (Pre > Post). Red solid line represents increase heart rate subjects (Pre < Post).

8.7 Change in QTc interval Using the Rubal (a novel linear regression) Method

The Bazett and Fridericia methods for QT correction were proposed in 1920. The Framingham method was proposed in 1992 to reduce the QTc estimation errors associated with prior methods. Luo et al. (2004) point out that none of these methods fully removes the influence of heart rate from estimating QT interval.⁵

For the present data, the relationship between QT and RR interval (inverse of heart rate) is illustrated in Figure 8. A strong correlation ($r = 0.87, p < 0.001$) can be seen between QT and RR interval for the unadjusted subject EKGs. Correcting QT interval as a function of RR interval variability eliminates the correlation ($r = 0.8E^{-6}, p = 0.999$) between QTc and RR interval, as shown in Figure 8. Appendix D provides greater detail about the Rubal method for QTc adjustment.




Figure 7. QT interval unadjusted for RR interval.




Figure 8. QT interval after linear regression adjustment for RR interval.

Table 6

Change in QTc interval using Rubal Method (ms)

Subject ID	Pre	Post	Change
A	427	398	-29
B	429	452	23
C	454	468	14
D	429	435	6
E	410	408	-3
F	375	414	38
G	406	421	14
H	415	420	5
I	447	423	-24
J	426	407	-19
K	422	429	7
L	366	428	63
M	402	408	6
N	465	434	-31
O	390	394	4
P	411	406	-4
Q	426	459	33
R	401	460	59
S	399	380	-19
T	370	398	29
U	465	564	99
V	452	453	1
W	413	436	23
X	348	471	123
Mean	414	432	17




Figure 9. Individual subjects' QTc change using Rubal method (units = ms). Green dotted line represents decrease heart rate subjects (Pre > Post). Red solid line represents increase heart rate subjects (Pre < Post).

8.8 Summary QT interval Change

A t-test of Pre- and Post-QT intervals for all subjects shows a significant lengthening of the QTc interval using the Rubal method ($p = 0.03$), non-significant difference using the Bazett and Framingham methods, and a trend using the Fridericia method ($p = 0.6$). The magnitude of the change for any method does not reach the 30 ms clinical significance threshold.

Table 7

Comparison of Mean QT interval Change Calculation Methods

QTc	<i>M</i>	<i>t</i>	<i>p</i>	<i>r</i>
Bazett				
Pre	391	1.47	0.16	0.29
Post	402			
Fridericia				
Pre	382	2.00	0.06	0.38
Post	394			
Framingham				
Pre	384	1.39	0.18	0.28
Post	393			
Rubal				
Pre	414	2.25	0.03	0.42
Post	432			

Note. M = mean; t = t-test statistic; p = p-value; r = correlation (effect size).

Table 8

Magnitude of QTc Exceeding Thresholds

QTc	440 ms		450 ms		480 ms	
	Pre	Post	Pre	Post	Pre	Post
Bazett	1	5	1	3	0	1
Fridericia	0	1	0	1	0	1
Framingham	0	1	0	1	0	1
Rubal	5	7	5	7	0	1

Note. N = 24

8.9 QT Lengthening Versus QT Shortening Analysis

In Sections 8.2 and 8.7, the mean changes in heart rate and QTc interval, respectively, do not show any clinically significant difference. Visual inspection of the pre- and post-exposure results suggest that the subjects are divided into two groups, those with an increase in heart rate and/or QTc interval and those with a decrease in heart rate and/or QTc interval. Increased QTc interval carries a risk of future adverse cardiac events. It is possible that two subpopulations have opposite responses to HEMI exposure, with the

opposing effects canceling any mean effect. Examining the subpopulations was undertaken to determine if an increase in QTc interval was present using threshold values of 40 ms from clinical care guidelines (Drew et al. 2010), plus 30 ms and 60 ms from the FDA Guidelines for Industry (US Dept. HHS).^{11,12} Analyzing the pre- and post-exposure data using the four methods of QTc calculation showed the following QTc differences.

Table 9

QTc Shortening versus QTc Lengthening

QTc	QTc Shortening				QTc Lengthening			
	<i>M</i>	<i>n</i>	<i>t</i>	<i>r</i>	<i>M</i>	<i>n</i>	<i>t</i>	<i>r</i>
Bazett								
Pre	396	11	-5.83***	0.88	386	13	4.38***	0.78
Post	375				425			
Fridericia								
Pre	384	9	-5.38***	0.88	381	15	3.74**	0.71
Post	371				409			
Framingham								
Pre	390	11	-4.86***	0.84	379	13	4.37***	0.78
Post	372				410			
Rubal								
Pre	426	7	-4.37**	0.87	409	17	3.78**	0.69
Post	408				442			

Note. M = mean; t = t-test statistic; r = correlation (effect size).

p* < 0.05, ** *p* < 0.01, * *p* < 0.001.

EKGs showed significant change in mean QTc interval with each of the four methods for QTc calculation found within both the QTc shortening and QTc lengthening sub-groups.

QTc shortening has been suggested as a risk for adverse cardiac events. In one study a lower QTc interval of ≤ 377 ms was associated with a hazard ratio of 1.36 for cardiovascular disease mortality.¹⁹ The Bazett, Fridericia, and Framingham methods for calculating QTc interval all identify eight or nine subjects with a pre-exposure QTc ≤ 377 ms and six or seven subjects with a post-exposure QTc ≤ 377 ms. The Rubal method identifies four subjects with a pre-exposure QTc ≤ 377 ms and no subject with a post-exposure QTc ≤ 377 ms. Using the Rubal method, the four subjects showed post-exposure QTc lengthening above 377 ms and none of the other subjects showed QTc shortening to ≤ 377 ms. These results suggest the Rubal method is superior when

evaluating an EKG for QTc shortening. Because this study was not designed to examine QTc shortening, it will not be discussed further.

Using the Bazett and Framingham methods, 13 of 24 subjects had a statistically significant lengthening of the QTc interval. The Fridericia method showed 15 of 24 subjects with a statistically significant longer QTc interval. The Rubal method showed 17 of 24 subjects with a QTc statistically significant lengthening. Examining the mean for subjects with QTc lengthening, the Framingham, Rubal, and Bazett methods all showed a change greater than 30 ms, the FDA defined borderline threshold. The Bazett method also showed QTc lengthening just shy of the alert levels of 40 ms clinically significant threshold. Examining individual responses using the four QTc calculation methods showed the FDA threshold for prolonged QTc change of 60 ms was exceeded by two subjects using the Bazett, Fridericia, and Framingham methods. The Rubal method showed three subjects with a QTc interval exceeding 60 ms and a fourth subject at 59 ms.

Table 10

QTc Lengthening Exceeding Thresholds

QTc	# Exceeding 30 ms	# Exceeding 40 ms	# Exceeding 60 ms
Bazett	5/13	5/13	2/13
Fridericia	5/15	4/15	2/15
Framingham	5/13	5/13	2/13
Rubal	6/17	4/17	3/17

One subject exceeded the 500 ms threshold post-exposure for all four methods, considered a significant risk for adverse cardiac events. This subject also exceeded the threshold for a prolonged QTc interval before HEMI exposure using the Bazett and Rubal methods, suggestive of an underlying long QT syndrome. Identification of this individual was not possible before HEMI exposure. This subject's results reveal nothing about the general population prevalence of QTc exceeding 500 ms after a 5-second HEMI exposure. Tables 11 through 14 show the results of repeating the analyses after removing this subject. The Rubal linear regression was recalculated using $N = 23$, so the resulting calculations yielded slightly different results.

Table 11

Comparison of Mean QT interval Change Calculation Methods (N = 23)

QTc	M	t	p	r
Bazett				
Pre	388	1.11	0.28	0.23
Post	396			
Fridericia				
Pre	380	1.66	0.11	0.33
Post	389			
Framingham				
Pre	381	1.03	0.31	0.21
Post	388			
Rubal				
Pre	410	1.88	0.07	0.37
Post	424			

Note. M = mean; t = t-test statistic; p = p-value; r = correlation (effect size).

A t-test of Pre- and Post-QT interval for all subjects no longer shows a significant lengthening of the QTc interval using any of the four methods, though a trend is seen using the Rubal method ($p = .07$). The magnitude of the change for any method does not reach the 30 ms clinical significance threshold.

Table 12

Magnitude of QTc Exceeding Thresholds (N = 23)

QTc	440 ms		450 ms		480 ms	
	Pre	Post	Pre	Post	Pre	Post
Bazett	0	4	0	2	0	0
Fridericia	0	0	0	0	0	0
Framingham	0	0	0	0	0	0
Rubal	4	6	4	6	0	0

Table 13

QTc Shortening versus QTc Lengthening (N = 23)

QTc	QTc Shortening				QTc Lengthening			
	<i>M</i>	<i>n</i>	<i>t</i>	<i>r</i>	<i>M</i>	<i>n</i>	<i>t</i>	<i>r</i>
Bazett								
Pre	396	11	-5.83***	0.88	381	12	4.04**	0.77
Post	375				416			
Fridericia								
Pre	384	9	-5.38***	0.88	377	14	3.45**	0.69
Post	371				401			
Framingham								
Pre	390	11	-4.86***	0.84	374	12	4.04**	0.77
Post	372				402			
Rubal								
Pre	427	8	-3.87**	0.83	401	15	3.45**	0.68
Post	411				430			

Note. M = mean; t = t-test statistic; r = correlation (effect size).

* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

EKGs still showed significant difference in mean pre- versus post-exposure QTc interval with each of the four methods for QTc calculation for the QTc lengthening sub-group.

Using the Bazett and Framingham methods, 12 of 23 subjects had a statistically significant lengthening of the QTc interval. The Fridericia method showed 14 of 23 subjects with a statistically significant longer QTc interval. The Rubal method showed 15 of 23 subjects with a QTc statistically significant lengthening. Examining the mean for subjects with QTc lengthening, only the Bazett method showed a change greater than 30 ms, the FDA defined borderline threshold. The Fridericia, Framingham, and Rubal methods showed mean changes of 24, 28, and 29 ms, respectively. Examining individual responses using the four QTc calculation methods showed the FDA threshold for prolonged QTc change of 60 ms was exceeded by one subject using the Bazett, Fridericia, and Framingham methods. The Rubal method showed two subjects with a QTc interval exceeding 60 ms and a third subject at 59 ms.

Table 14

QTc Lengthening Exceeding Thresholds (N = 23)

QTc	# Exceeding 30 ms	# Exceeding 40 ms	# Exceeding 60 ms
Bazett	4/12	4/12	1/12
Fridericia	4/14	3/14	1/14
Framingham	4/12	4/12	1/12
Rubal	4/15	3/15	2/15

9.0 DISCUSSION

The results of this study show that lengthening of the QT interval can occur after a single 5-second HEMI exposure. Several methods exist for correcting the QT interval to remove the influence of heart rate, or inverse of RR interval. Refer to Table 7 for a summary comparison of mean QTc interval changes. The Bazett, Fridericia, and Framingham methods are recognized as useful by the FDA when assessing the impact of a pharmaceutical on QTc interval. The Bazett method is most widely used, but this method over-estimates QT interval for heart rates above 60 beats per minute. The Fridericia and Framingham methods for correcting QT interval are less influenced by heart rate, but still have significant unaccounted variability. The Rubal method accounts for almost all variability of QTc interval through a linear regression.

Two population subsets appear to be present, those who respond to HEMI exposure with QTc lengthening and those who respond with QTc shortening. The QTc lengthening and shortening both reach statistical significance. A smaller subset of subjects show a mean QTc lengthening that exceeds one or more thresholds for risk of adverse cardiac events. One subject appears to be an outlier, with a baseline QTc interval exceeding 450 ms for both the Bazett and Rubal methods, and post-exposure QTc interval exceeding 500 ms for all four methods. It is possible that this individual has an underlying congenital QT prolongation, as previously noted to have prevalence estimates from 1/20,000 to 1/2,500.⁶ After removing this subject's data, mean QTc lengthening and shortening are still statistically significant for all four QTc correction methods. The mean QTc lengthening exceeds QTc variability of 16 ms for all four methods.

The clinical or operational significance of QTc interval change can be assessed by absolute magnitude or relative change in QTc interval. In practice a common clinical threshold for QTc interval with an increased risk of adverse cardiac events is ≥ 440 ms.^{20,21,22} These three studies calculated the risk of adverse cardiac events using the Bazett method. In comparison the FDA uses 450 ms and 480 ms thresholds for identifying the risk of adverse cardiac events. Both the Bazett and Fridericia methods for correcting QTc interval are requested by the FDA, plus acceptance of the Framingham method if the submitter chooses to provide additional results. After HEMI exposure, using the Bazett method and n = 23, four subjects have a QTc interval greater than 440

ms and two subjects exceed 450 ms. The Fridericia and Framingham methods do not identify any subject as exceeding the 440 ms threshold. The Rubal method identifies four subjects exceeding 440 ms before HEMI exposure, six exceeding 440 ms after exposure, three subjects exceeding 450 ms before exposure and six subjects exceeding this threshold after exposure. Except for the one outlier removed from this discussion, no subject exceeded 480 ms before or after HEMI exposure using any of the four QTc calculation methods. The subjects in the current study represent a healthier population from the populations in the three studies that identified a risk when QTc exceeds 440 ms. None of the subjects in the current study have a history of heart disease and all engage in regular aerobic exercise as part of military fitness training. These differences likely place the subjects with QTc intervals exceeding 440 ms after HEMI exposure at borderline risk for adverse cardiac events.

The FDA also specifies change in QTc interval of 30 ms as borderline and 60 ms as significant for risk of an adverse cardiac event. A 40 ms increase in QTc interval was chosen as a threshold level for the current study prior to knowledge of the FDA thresholds. In the current study, with the outlier removed, one third of subjects exceed a 40 ms change in QTc interval, using the Bazett and Framingham methods. Approximately one fifth of subjects exceed a 40 ms QTc change using the Fridericia and Rubal methods. One subject exceeds a 60 ms QTc change by all four methods. These results indicate that a sizable minority of subjects develop a borderline or significant change in QTc interval after a single 5-second HEMI exposure.

It is possible that the combination of medication(s) and electrical shock, both reported to lengthen the QT interval, results in clinically defined QT prolongation not seen with either exposure alone. One review of HEMI safety for law enforcement noted over 70% of individuals subdued using HEMI had intoxicating drugs in the urine. Cocaine was the most common substance detected at 40% for individuals who were screened.²³ A detailed list of medications that can cause QT prolongation can be found at www.Crediblemeds.org.²⁴ Exploring drug-HEMI interactions was beyond this current investigation, but should be considered as part of the critical assessment for HEMI exposure under operational conditions. Certainly adding combinations of common pharmaceutical and/or abuse drug use should be a basis for future HEMI effects research.

The cardiac action potential is shown below in Figure 2. The QT interval consists of phases 0 through 3. Opening of the potassium channels during phase 3 repolarizes or returns the membrane potential toward the resting state. Blocking the potassium repolarizing current channel (I_{Kr}) prevents the outflow of potassium from cardiac myocytes, prolonging the QT interval.²⁵ It is possible that HEMI can result in dysfunction of the I_{Kr} channels. Why some people but not others experience this effect is unclear. It is possible that genetic variation of the proteins comprising the I_{Kr} channels predisposes people to the development of QTc lengthening after HEMI exposure.




Figure 10. Cardiac action potential (adapted from Chapter 21 Electrocardiography in Medical Physiology²⁶)

Another important question not addressed in this study is: Do multiple HEMI exposures have a greater influence on QT prolongation? No investigations have been found in the literature. Concerning longer HEMI exposures, two published studies have evaluated the effects of extended duration HEMI exposures. Dawes et al. studied 11 volunteers exposed for 30 seconds to HEMI from a TASER C2 device. Before and after exposure EKGs were evaluated by a cardiac electrophysiologist who was blind to the identity of the subjects. Result descriptions were limited to rate, rhythm, and possible ST depression. No comment was provided about QT interval.²⁷ A second study by Dawes et al. exposed 53 volunteers to a TASER X3 device for 10 seconds. No EKG results were reported.²⁸ Does this change for an individual with HEMI exposures on different days?

These questions and others should be considered for future research, especially a study QT lengthening after extended duration HEMI exposures.

10.0 CONCLUSIONS

Twenty-four healthy volunteers were investigated using EKG after receiving a 5-second HEMI exposure as part of USAF Security Forces training. Standard 12-lead EKGs were obtained before exposure and less than 30 minutes after the single 5-second exposure. All EKGs were analyzed for RR and QT intervals. The QT interval was corrected for RR variability by four methods, Bazett, Fridericia, Framingham, and Rubal, a novel linear regression method. Two subpopulations were identified, those who developed QTc shortening and those who developed QTc lengthening. Both subpopulations had statistically significant changes in QTc interval. One third of one subpopulation were found to exceed the FDA threshold for borderline QTc lengthening. A single individual with existing pre-exposure QTc prolongation exceeded a 500 ms threshold for significant risk of adverse cardiac events.

REFERENCES

1. Blackwell N, Hayllar J. A three year prospective audit of 212 presentations to the emergency department after electrical injury with a management protocol. *Postgrad Med J.* 78(919):283-285.
2. Levine SD, Sloane CM, Chan TC, Dunford JV, Vilke GM. Cardiac monitoring of human subjects exposed to the Taser. *J Emerg Med.* 2007;33(2):113-117.
3. Ho JD, Miner JR, Lakkireddy DR, Bultman LL, Heegaard WG. Cardiovascular and physiologic effects of conducted electrical weapon discharge in resting adults. *Acad Emerg Med.* 2006;13(6):589-595.
4. VanMeenen KM, Cherniack NS, Bergen MT, Gleason LA, Teichman R, Servatius RJ. Cardiovascular evaluation of electronic control device exposure in law enforcement trainees: a multisite study. *J Occ Environ Med.* 2010;52(2):197-201.
5. Luo S, Michler K, Johnston P, Macfarlane PW. A comparison of commonly used QT correction formulae: The effect of heart rate on QTc of normal ECGs. *J Electrocardiol.* 2004, 37 Suppl:81-90.
6. Crotti L, Celano G, Dagradi F, Schwartz PJ. Congenital long QT syndrome. *Orphanet J Rare Dis.* 2008;3:18.
7. Yee GY, Camm AJ. Drug induced QT prolongation and torsades de pointes. *Heart.* 2003;89(11):1363-1372.
8. Hanon S, Seewald RM, Yang F, Schweitzer P, Rosman J. Ventricular arrhythmias in patients treated with methadone for opioid dependence. *J Interv Card Electrophysiol.* 2010;28(1):19-22.
9. Hoffman RS. Treatment of patients with cocaine-induced arrhythmias: bringing the bench to the bedside. *Brit J Clin Pharm.* 2010;69(5):448-457.
10. Moss AJ. The QT interval and torsades de pointes. *Drug Safety.* 1999; 21 Suppl 1:5-10.
11. Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, Zareba W. Prevention of torsades de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. *Circulation.* 2010 Mar 2; 121(8):1047-1060.
12. U.S. Department of Health and Human Services, Food and Drug Administration. *Guidance for Industry E14 Clinical Evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-arrhythmic drugs*, Oct 2005.
13. Hnatkova K, Kowalski D, Keirns JJ, van Geldered EM, Malik M. Relationship of QT interval variability to heart rate and RR interval variability. *J Electrocardiol* 2013;46(6):591-596.
14. Browne KF, Prystowsky E, Heger JJ, Chilson DA, Zipes DP. Prolongation of the QT interval in man during sleep. *Am J Cardiol* 1983;52(1): 55-59.
15. Garson A. How to measure the QT interval - what is normal? *Am J Cardiol* 1993;72(6):14B-16B.

16. Viskin S, Rosovoski U, Sands AJ, Chen E, Kistler PM, Kalman JM, Rodriguez Chavez L, Iturralde Torres P, Cruz FFE, Centurion OA, Fujiki A, Maury P, Chen X, Krahn AD, Roithinger F, Zhang L, Vincent GM, Zeltser D. Inaccurate electrocardiographic interpretation of long QT: the majority of physicians cannot recognize a long QT when they see one. *Heart Rhythm* 2005;2(6):569-574.
17. Brave M. (2016, April 8). TASER X26 electronic control devices electrical characteristics. Retrieved from www.ecdlaw.info/outlines/EC_02-01-09_X26_Elec_Char.pdf.
18. Air Force Guidance Memorandum 4 to Air Force Instruction 48-123 *Medical Examinations and Standards*, 29 Jan 2013.
19. Zhang Y, Post WS, Dalal D, Blasco-Colmenares E, Tomaselli GF, Guallar E. QT-interval duration and mortality rate. *Arch Int Med* 2011;171(19):1727-1733.
20. Schouten EG, Dekker JM, Meppelink P, Kok FJ, Vandenbroucke JP, Pool J. QT interval prolongation predicts cardiovascular mortality in an apparently healthy population. *Circulation*; 84(4):1516-1523.
21. Goldberg RJ, Bengtson J, Chen Z, Anderson KM, Locati E, Levy D. Duration of the QT interval and total and cardiovascular mortality in healthy persons (The Framingham Heart Study experience). *Am J Cardiol*; 67(1):55-58.
22. Algra A, Tijssen JGP, Roelandt JRTC, Pool J, Lubsen J. QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest. *Circulation*; 83(6):1888-1894.
23. Strote J, Walsh M, Angelidis M, Basta A, Hutson HR. Conducted electrical weapon use by law enforcement: An evaluation of safety and injury. *J Trauma* 2010;68:1239-1246.
24. Woosley, RL and Romero, KA, www.Crediblemeds.org, QTdrugs List, Accessed on 9 Dec 2015, AZCERT, Inc. 1822 Innovation Park Dr., Oro Valley, AZ 85755
25. Haverkamp W, Breithardt G, Camm AJ, Janse MJ, Rosen MR, Antzelevitch C, Escande D, Franz M, Malik M, Moss A, Shah R. The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. *Cardiovasc Res.* 2000;47(2):219-233.
26. Ledderer WJ (2012). Electrocardiography in Boron WF and Boulpaep EL (Eds.), *Medical Physiology* (2nd ed.) (page 508) Philadelphia, PA: Saunders.
27. Dawes DM, Ho JD, Reardon RF, Miner JR (2010). The cardiovascular, respiratory, and metabolic effects of a long duration electronic control device exposure in human volunteers. *Forensic Sci Med Pathol*; 6:268-274.
28. Dawes DM, Ho JD, Reardon RF, Strote SR, Nelson RS, Lundin EJ, Orozco BS, Kunz SN, Miner JR (2011b). The respiratory, metabolic, and neuroendocrine effects of a new generation electronic control device. *Forensic Sci Int*; 207(1-3):55-60.

APPENDIX A – Medical Screening Form

Subject ID #: _____

Part I - Directions:

These questions are being asked to ensure your safety in this study

Circle YES – If any of the below medical conditions or medications apply to you.

Circle NO – If ALL of the listed medical conditions and medications do NOT apply to you.

Circle UNSURE – If you do not know about any of the listed medical conditions or medications.

Do Not Circle any Individual Medical Condition or Medication.

1. Do you have a medical waiver for continued military service? YES NO UNSURE

2. Do you have or ever had any of the following medical conditions? YES NO UNSURE

Congestive heart failure

Abnormal heart rhythm, fast or slow

Irregular heartbeats that make you short of breath or lightheaded

Recurrent chest pains

Angina with mild to moderate exercise

Heart attack

Cardiac pacemaker

Implanted cardioverter-defibrillator (AICD)

Irritated heart muscle (Cardiomyopathy)

Delay in heartbeat conduction (heart block)

2. Do you currently take any of the following medications? YES NO UNSURE

Antiarrhythmic drugs

Amiodarone (Cordarone)

Bretylum (Bretylol)

Disopyramide (Norpace)

Dofetilide (Tikosyn)

Flecainide (Tambocor)

Ibutilide (Corvert)

Procainamide (Pronestyl, Procan)

Quinidine (Quinidex, Quinaglute)

Sotalol (Betapace)

(over)

Do you currently take any of the following medications? (cont.)

YES NO UNSURE

Psychiatric drugs

Amitriptyline (Elavil)
Chlorpromazine (Thorazine)
Clomipramine (Anafranil)
Desipramine (Norpramin)
Doxepin (Adapin)
Droperidol (Inapsine)
Fluoxetine (Prozac, Sarafem)
Haloperidol (Haldol)
Imipramine (Tofranil)
Lithium (Eskalith, Lithobid)
Maprotiline (Ludiomil)
Nortriptyline (Pamelor)
Pimozide (Orap)
Thioridazine (Mellaril)
Ziprasidone (Geodon, Zeldox)

Antimicrobial drugs

Amantadine (Symmetrel)
Chloroquine (Aralen)
Clarithromycin (Biaxin)
Erythromycin (E-Mycin, Ery-Tab)
Fluconazole (Diflucan)
Halofantrine (Halfan)
Ketoconazole (Nizoral)
Pentavalent antimonial meglumine (Glucantime)
Sparfloxacin (Zagam)

Antihistamines

Diphenhydramine (Benadryl)
Hydroxyzine (Atarax)
Loratidine (Claritin)

Miscellaneous

Cocaine
Organophosphates (pesticides)
Papaverine
Tacrolimus (Prograf)

APPENDIX B - Selvester QRS Screening Criteria

The Selvester QRS screening criteria were used to identify Q-wave infarction.

- (1) Q wave of ≥ 30 ms in aVF (inferior);
- (2) Q wave of ≥ 40 ms in I and aVL (lateral);
- (3) Q wave of ≥ 40 ms in $\geq$ two of V4 through V6 (apical);
- (4) R wave of ≥ 40 ms in V1 (posterior); (5) any Q wave in V2 (anterior); and
- (5) R wave ≤ 0.1 mV and 10 ms in lead V2 (anterior).

APPENDIX C - Cardiac Medical Conditions Disqualifying for Military Service

<u>Disqualifying for continued military service</u>	<u>Comments</u>
Congestive heart failure	Heart inadequately pumps blood, poor exercise tolerance
Persistent major rhythm disturbances	At risk for sudden cardiac death
Repeated angina attacks	Chest pain = warning sign of potential heart attack
Silent ischemia at low to moderate workload	Can only be diagnosed with exercise test
Evidence of myocardial infarction	Found on EKG when otherwise asymptomatic (silent heart attack)
Medication for treatment or prevention of: Angina Congestive heart failure Major rhythm disturbance (ventricular tachycardia, ventricular fibrillation, symptomatic paroxysmal supraventricular tachycardia, atrial flutter, or atrial fibrillation)	Some of the same medications are used to manage high blood pressure, migraines, and other medical conditions
Pacemaker or implanted cardioverter defibrillator Cardiomyopathy	Identified at risk for sudden death
Symptomatic premature ventricular contractions that interfere with satisfactory performance of duty	Satisfactory performance is the key
Second degree Type II or third degree heart block	At risk for sudden death
Symptomatic second degree Type I heart block	Symptomatic condition is the key

APPENDIX D - Rubal Method for Correcting QT Interval Based on RR Interval

Rubal scores are constructed from RR Interval (sec) and QT (ms) scores (see Table 15 below). Using these values, we calculated: QT/RR, average of all 48 QT/RR measurements (mean = $\bar{y}$ = 423.13), and predicted QT/RR from a regression analysis using RR interval (sec) as an independent variable (see Figure 11 below, top figure). This analysis yielded a regression line equation for predicted QT/RR scores ($y = -369.55x + 758.81$) and was used to calculate the predicted QT/RR scores for each subject. A strong correlation between RR interval and QT interval can be seen, with $R^2 = 0.76$. The influence of RR interval on QT interval was significantly reduced using the following equation.

$$QTc \text{ (Rubal)} = y - y' + \bar{y}$$

y = measured QT/RR

y' = Predicted of QT/RR

$\bar{y}$ = Average of all QT/RR

We named these new values Rubal, because Bernard Rubal, Ph.D., our physiologist collaborator, suggested this method to strongly reduce the influence RR intervals have on QT intervals. To demonstrate the variability associated with RR intervals was significantly reduced, we ran a regression predicting Rubal scores using RR intervals as an independent variable. As expected, RR interval scores did not influence Rubal scores, as indicated by a low r (see Figure 11, bottom figure). Furthermore, QTc (Rubal) is currently the only method that is not contaminated by RR intervals: Bazett, Fridericia, and Framingham are highly correlated with RR intervals (see Table 16).

Table 15

Raw scores for RR Interval (sec), QT Interval (ms), QT/RR, Predicted QT/RR, and QTc (Rubal)

Subject ID	RR Interval (sec)		QT (ms)		QT/RR		Predicted QT/RR		QTc (Rubal)	
	Pre	Post	Pre	Post	Pre	Post	Pre	Post	Pre	Post
A	1.02	0.88	393	360	387	408	383	432	427	398
B	0.70	0.77	353	387	507	504	501	475	429	452
C	0.95	0.79	417	403	439	513	408	468	454	468
D	0.88	0.97	387	400	439	411	434	399	429	435
E	0.71	0.81	343	360	484	443	496	458	410	408
F	0.89	1.03	340	380	383	370	431	379	375	414
G	0.88	1.16	367	380	417	328	434	330	406	421
H	0.84	0.79	370	367	439	462	447	466	415	420
I	0.73	0.78	373	367	514	470	490	471	447	423
J	0.78	0.91	370	370	472	405	469	421	426	407
K	0.73	0.65	357	340	486	526	488	520	422	429
L	0.76	0.66	320	343	419	520	477	515	366	428
M	0.85	0.96	360	373	422	388	443	403	402	408
N	1.32	1.07	413	400	314	374	272	363	465	434
O	1.07	0.97	353	360	331	371	365	400	390	394
P	1.01	0.82	377	360	374	439	387	456	411	406
Q	1.11	1.38	390	393	351	285	349	249	426	459
R	0.86	0.88	360	413	419	471	441	435	401	460
S	0.81	0.88	353	343	434	392	458	435	399	380
T	0.96	1.21	337	347	351	286	404	310	370	398
U	0.80	0.75	403	467	506	622	464	482	465	564
V	1.08	1.17	420	417	388	355	358	325	452	453
W	1.09	0.96	377	400	346	417	356	404	413	436
X	0.84	0.68	313	377	373	557	448	509	348	471

Figure 11. QT/RR and Rubal Method




Table 16

Correlations (r) between QTc and RR interval

RR Interval	QTc			
	Bazett	Framingham	Fridericia	Rubal
	-0.64***	-0.52***	-0.38**	-0.8E ⁻⁵ ***

* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.